Found 161 articles for: "ustekinumab"
Efficacy of Topical Herbal Anti-inflammatory Treatment (HAT1) for Treating Psoriasis: An Investigator-Initiated Open Label Study
August 2021 | Volume 20 | Issue 8 | Editorials | 912 | Copyright © August 2021
Atopical botanical complex from a novel combination of phytochemicals, denoted as herbal anti-inflammatory treatment 1 (HAT1), was developed for topical treatment of psoriasis....
Read MoreEffect of Ixekizumab on Patient Reported Outcomes and Quality of Life in Patients With Moderate-to-Severe Plaque Psoriasis: 5-Year Results from the UNCOVER-1 and -2 Studies
April 2021 | Volume 20 | Issue 4 | Original Article | 394 | Copyright © April 2021
Objective: We describe patient-reported outcomes and quality of life through 5 years of treatment in patients with moderate-to-severe plaque Read More
A Retrospective Review of Patients’ Response to Biologic Therapy for Psoriasis
April 2021 | Volume 20 | Issue 4 | Original Article | 442 | Copyright © April 2021
Background: Biologic treatments have taken the forefront in treating moderate-to-severe psoria...
Read MoreHospitalization in Patients with Psoriasis: Impact of Biological Therapies on Temporal Evolution
February 2021 | Volume 20 | Issue 2 | Original Article | 208 | Copyright © February 2021
Background: Psoriasis is an immunomediated disease mostly controlled at the outpatient level, although there is a low percentage of patients that require systemic drugs or even hospit...
Read MoreCOVID-19 Vaccine and Biologics: An Impending Dilemma
January 2021 | Volume 20 | Issue 1 | Editorials | 115 | Copyright © January 2021
The COVID-19 pandemic has forced healthcare providers across all specialties to adjust their methods of clinical practice. I...
Read MoreUveitis for Dermatologists: A Review
December 2020 | Volume 19 | Issue 12 | Original Article | 1192 | Copyright © December 2020
Certain dermatologic conditions and drugs used for their treatment are associated with uveitis, a vision-threatening group of inflammatory eye diseases. Dermatologists may therefore be the first healt...
Read MorePredicting Secukinumab Fast-Responder Profile in Psoriatic Patients: Advanced Application of Artificial-Neural-Networks (ANNs)
December 2020 | Volume 19 | Issue 12 | Editorials | 1241 | Copyright © December 2020
Background: Drug resistance to biologics in psoriasis therapy can occur – it may be acquired during a treatment or else present itself from the beginning. To date, no biomarkers...
Read MoreTherapies for Psoriasis: Clinical and Economic Comparisons
November 2020 | Volume 19 | Issue 11 | Original Article | 1101 | Copyright © November 2020
Background: Clinical and economic comparisons of therapies for plaque psoriasis are regularly updated following each new devel- opment in the field. With the recent availability of a ...
Read MoreRemission of Refractory PASH Syndrome Using Ixekizumab and Doxycycline
November 2020 | Volume 19 | Issue 11 | Editorials | 1124 | Copyright © November 2020
Increased Trend of Cosmetic Procedures in Patients With Psoriasis Who Attain 75% or Greater Improvement
August 2020 | Volume 19 | Issue 8 | Original Article | 698 | Copyright © August 2020
Background: The relationship between the clearance of psoriasis and improved quality of life together with an increased uptake of cosmetic procedures has not been reported to date.
Read More Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis
August 2020 | Volume 19 | Issue 8 | Original Article | 741 | Copyright © August 2020
Background: Presence of nail psoriasis in patients with plaque psoriasis may be an indicator of greater disease severity. Previously, patients with nail psoriasis have had delayed ski...
Read MoreOne-Year Pharmacovigilance Update of Brodalumab
August 2020 | Volume 19 | Issue 8 | Editorials | 807 | Copyright © August 2020
The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2)
August 2020 | Volume 19 | Issue 8 | Original Article | 703 | Copyright © August 2020
Background: Metabolic syndrome (MetS) is the most prevalent comorbidity in psoriasis and increases the risk of cardiovasc...
Read MoreSafety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) Errata
June 2020 | Volume 19 | Issue 6 | Editorials | 571 | Copyright © June 2020
Erratum for article "Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)." Retrieved from Read More
The New Psoriasis Paradigm: Striving for Complete Clearance
June 2020 | Volume 19 | Issue 6 | Original Article | 652 | Copyright © June 2020
Newer biologics have introduced the possibility of higher and more complete clearance rates than previously possible. For many patients, PASI 90 and PASI 100 responses are realistic. Furthermore, high...
Read MoreImportance of Complete Skin Clearance in Psoriasis as a Treatment Goal: Implications for Patient-Reported Outcomes
May 2020 | Volume 19 | Issue 5 | Original Article | 487 | Copyright © May 2020
Psoriasis is associated with physical, psychological, social, and economic burdens that lead to substantial impairment over a patient&rsqu...
Read MoreTreatment of Plaque Psoriasis With an Excimer Laser Utilizing an Optimal Therapeutic UVB Dose Protocol
April 2020 | Volume 19 | Issue 4 | Original Article | 349 | Copyright © April 2020
Background: Traditionally, treatment with the excimer laser requires determining the minimal erythema dose on healthy skin or using plaque-based induration; however, these protocols o...
Read MoreIs the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?
April 2020 | Volume 19 | Issue 4 | Features | 436 | Copyright © April 2020
Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?...
Read MoreEvaluation of Patient-Reported Outcomes with Etanercept in Moderate to Severe Plaque Psoriasis Patients After Therapy With Apremilast
April 2020 | Volume 19 | Issue 4 | Original Article | 378 | Copyright © April 2020
Background: Patients with moderate-to-severe psoriasis can have symptoms resulting in significant impact on patient-reported outcomes (PROs). The effect of etanercept (ETN) in moderat...
Read MoreRecapture Rate of Brodalumab in Patients With a Lapse in Treatment
April 2020 | Volume 19 | Issue 4 | Original Article | 384 | Copyright © April 2020
The National Psoriasis Foundation has emphasized the importance of achieving skin clearance targets throughout the course of treatment. However, patients with psoriasis often stop and restart treatmen...
Read More